logo
Plus   Neg
Share
Email

FDA Panel Backs Pfizer's Xeljanz For Ulcerative Colitis

Pfizer Inc. (PFE) Thursday announced a favorable outcome of U.S. Food and Drug Administration Gastrointestinal Drugs Advisory Committee meeting on Pfizer's supplemental New Drug Application for Xeljanz (tofacitinib), which is currently under review by the FDA, for the treatment of adult patients with moderately to severely active ulcerative colitis.

"Today's discussion underscored the significant unmet need that exists for people living with ulcerative colitis, a disease that is often debilitating and difficult to control. We are encouraged about the positive outcome of today's GIDAC meeting," said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development.

"If approved, tofacitinib will be the first Janus kinase inhibitor and the first oral therapy for adults living with moderately to severely active ulcerative colitis. We look forward to working with the FDA as it completes the review of our pending application."

The role of the GIDAC is to provide recommendations to the FDA; however, the recommendations are not binding. FDA's decision on whether or not to approve tofacitinib for UC is expected by the Prescription Drug User Fee Act date in June 2018.

Ulcerative Colitis is a chronic and often debilitating inflammatory bowel disease that affects millions of people worldwide. Symptoms include chronic diarrhea with blood and mucus, abdominal pain and cramping, and weight loss.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The takeover battle by Comcast Corp. nd Rupert Murdoch's 21st Century Fox Inc. for British broadcaster Sky plc will be settled through an auction. The UK Takeover Panel said Thursday that an auction procedure is expected to commence on the evening of Friday, September 21, 2018 and end on the evening of September 22, 2018. The winner of the auction will be announced on Saturday. Luxury car maker Aston Martin on Thursday announced the pricing range for its planned initial public offering on the London Stock Exchange, valuing the company at up to $6.7 billion. The UK-based maker of the famed car favored by iconic spy James Bond, has set the price range for its IPO at 17.50 pounds to 22.50 pounds per ordinary share. Alibaba's founder and chairman Jack Ma has said that the Chinese e-commerce giant no longer plans to create 1 million jobs in the US, citing the ongoing trade conflict between the US and China as the reason. "The promise was made on the premise of friendly US-China partnership and rational trade relations,"...
Follow RTT